Post-Trial Judicial Review of Criminal Convictions: A Comparative Study of the United States and Finland
In: Maine Law Review, Band 64, Heft 2, S. 1
7 Ergebnisse
Sortierung:
In: Maine Law Review, Band 64, Heft 2, S. 1
SSRN
In: Journal of Latin American studies, Band 40, Heft 4, S. 834-836
ISSN: 1469-767X
In: Journal of Latin American studies, Band 40, Heft 4, S. 834-836
ISSN: 0022-216X
In: Journal of Latin American studies, Band 40, Heft 4, S. 834-835
ISSN: 0022-216X
In: IEEE antennas & propagation magazine, Band 49, Heft 1, S. 82-91
ISSN: 1558-4143
SLAMF9 is an orphan receptor of the CD2/SLAM family of leucocyte surface proteins. Examination of SLAMF9 expression and function indicates that SLAMF9 promotes inflammation by specialized subsets of antigen presenting cells. Within healthy liver and circulating mouse PBMCs, SLAMF9 is expressed on CD11b+, Ly6C-, CD11clow , F4/80low , MHC-II+, CX3 CR1+ mononuclear phagocytes as well as plasmacytoid dendritic cells. In addition, SLAMF9 can be found on peritoneal B1 cells and small (F4/80low ), but not large (F4/80high ), peritoneal macrophages. Upon systemic challenge with Salmonella enterica Typhimurium, Slamf9-/- mice were impaired in their ability to clear the infection from the liver. In humans, SLAMF9 is up-regulated upon differentiation of monocytes into macrophages, and LPS stimulation of PMA-differentiated, SLAMF9 knockdown THP-1 cells showed an essential role of SLAMF9 in production of GM-CSF, TNFα, and IL-1β. Taken together, these data implicate SLAMF9 in the initiation of inflammation and clearance of bacterial infection. ; These studies were supported by grants from: the European Union FP7 Infectious Triggers of Chronic Autoimmunity Consortium (CP-FP 261382); the Wellcome Trust (grant 206194); and the National Institutes of Health (R15-AI138184). KGCS is supported by the Medical Research Council (programme grant MR/L019027) and is a Wellcome Investigator.
BASE
In: PNAS nexus, Band 3, Heft 1
ISSN: 2752-6542
Abstract
A number of intrinsically disordered proteins (IDPs) encoded in stress-tolerant organisms, such as tardigrade, can confer fitness advantage and abiotic stress tolerance when heterologously expressed. Tardigrade-specific disordered proteins including the cytosolic-abundant heat-soluble proteins are proposed to confer stress tolerance through vitrification or gelation, whereas evolutionarily conserved IDPs in tardigrades may contribute to stress tolerance through other biophysical mechanisms. In this study, we characterized the mechanism of action of an evolutionarily conserved, tardigrade IDP, HeLEA1, which belongs to the group-3 late embryogenesis abundant (LEA) protein family. HeLEA1 homologs are found across different kingdoms of life. HeLEA1 is intrinsically disordered in solution but shows a propensity for helical structure across its entire sequence. HeLEA1 interacts with negatively charged membranes via dynamic disorder-to-helical transition, mainly driven by electrostatic interactions. Membrane interaction of HeLEA1 is shown to ameliorate excess surface tension and lipid packing defects. HeLEA1 localizes to the mitochondrial matrix when expressed in yeast and interacts with model membranes mimicking inner mitochondrial membrane. Yeast expressing HeLEA1 shows enhanced tolerance to hyperosmotic stress under nonfermentative growth and increased mitochondrial membrane potential. Evolutionary analysis suggests that although HeLEA1 homologs have diverged their sequences to localize to different subcellular organelles, all homologs maintain a weak hydrophobic moment that is characteristic of weak and reversible membrane interaction. We suggest that such dynamic and weak protein–membrane interaction buffering alterations in lipid packing could be a conserved strategy for regulating membrane properties and represent a general biophysical solution for stress tolerance across the domains of life.